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Preterm birth is defined as birth at < 37 weeks’
gestation. The frequency of preterm labor leads to
13 million preterm births worldwide, therefore,
it is a matter that needs recognition and attention.1
The incidence of preterm births in North America
is 11%, in Oceania, 5.6%, and in Europe, 5.8%,
which accounts for 400,000 preterm births annu-
ally. A retrospective cohort study of singleton preg-
nancies at the Chang Gung Memorial Hospital,
Taiwan reported a 1.4% early spontaneous pre-
term delivery rate (< 34 weeks of gestation).2
Statistical studies from the United States have
shown that preterm birth is accountable for two-
thirds of all neonatal deaths, excluding congenital
malformations.3
The use of tocolytic drugs to inhibit preterm
uterine contractions is a common treatment for
delaying delivery in preterm labor. According to
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the international guidelines for the management
of preterm labor, delaying delivery allows the ad-
ministration of a complete course of antepartum
glucocorticosteroids to the mother, to reduce the
severity of idiopathic respiratory distress syn-
drome and to arrange in utero transfer to a center
with neonatal intensive care facilities.4–6 The cur-
rent recommendation is a single course of gluco-
corticosteroids within 7 days to pregnant women
at risk of preterm delivery between 24 and 34
weeks gestation.5–7 Corticosteroids regulate the
production of lung surfactant, which takes 4–7
days to become effective following initial corti-
costeroid administration.8 This also reflects the
need for an effective tocolytic drug to delay pre-
term delivery for at least 7 days, in order for the
corticosteroid to be most effective.
A number of tocolytic agents are currently 
in use for the treatment of preterm labor, and
have shown different efficacy and safety. Some
are licensed for use (oxytocin receptor antagonist
and ritodrine in selected countries), but most are
not (nitric oxide donors, prostaglandin synthe-
tase inhibitors, magnesium sulfate and calcium
channel blockers and some beta-agonists). Only
one group of drugs was developed specifically to
treat spontaneous preterm labor (the oxytocin
receptor antagonist atosiban), and the others
were developed for other purposes. Unlike atosi-
ban, most of the other tocolytics are not utero-
specific, therefore, multi-organ fetomaternal side
effects are expected.1 Beta-agonists are often as-
sociated with maternal cardiovascular adverse
events, and in the past, reports of pulmonary
edema, cardiac arrhythmia and hypokalemia have
been common.9 Atosiban acts as a competitive
antagonist of oxytocin to inhibit oxytocin-induced
uterine contraction, and is the first oxytocin an-
tagonist designed for specific treatment of preterm
labor.10
Currently, clinical studies of tocolytic treat-
ment that targets Asian populations are scarce.
The objective of this trial was to compare the 
tocolytic efficacy and safety profile of atosiban
and ritodrine in the treatment of spontaneous
preterm labor in Taiwanese women. This study
was designed to monitor adverse events, with a
particular focus on tachycardia, which is fre-
quently associated with the conventional beta-
agonist therapy. This study will serve to provide
further clinical data on Asian populations. Previ-
ously, racial variation has been reported as a con-
tributor to different preterm frequency between
ethnic groups.11,12
Patients and Methods
This was a randomized, open label, controlled
trial, carried out in the obstetric department at
the Taiwan University Hospital, to compare the
tocolytic efficacy and safety of atosiban and rito-
drine in women diagnosed with spontaneous
preterm labor between July 26, 2002 and July 15,
2005. The study protocols and the written in-
formed consent were approved by the ethics com-
mittees and approved by the Institutional Review
Board of the National Taiwan University Hospi-
tal and the Taiwan Department of Health. Each
woman reviewed and voluntarily signed the writ-
ten consent form before enrolment.
A total of 45 patients were included in this
study after fulfilling the following inclusion crite-
ria: (1) regular uterine contractions (≥ 30 seconds
in duration, at a rate of ≥ 4 times in 30 minutes),
with cervical dilation of 0–3 cm and cervical ef-
facement of ≥ 50%; (2) ≥ 18 years of age; and (3)
gestational age of 24–33 weeks. Exclusion criteria
were: high-order multiple pregnancy (more than
twins); ruptured membranes; major vaginal bleed-
ing (continuous vaginal bleeding with fresh blood
or bleeding volume > 100 mL); pre-eclampsia or
hypertension (blood pressure > 140/90 mmHg);
fever > 37.5°C; urinary tract infection; fetal/
placental/amniotic abnormalities (e.g. major fetal
anomalies, chorioamnionitis, polyhydramnios,
fetal growth restriction or placenta previa); seri-
ous maternal disease (e.g. cardiovascular disease,
hyperthyroidism, diabetes, pheochromocytoma
or asthma); any contraindication to the use of
beta-agonists; alcohol or drug abuse; previous
exposure to nonsteroidal anti-inflammatory drugs
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for tocolysis within 12 hours of study entry; his-
tory of hypersensitivity to any component of the
study drugs and participation in a clinical trial
within 1 month.
Women were computer-randomized into two
groups to ensure that the two treatments were
equally distributed between the gestational age
subgroups. The investigational drug atosiban
(Tractocile®) was supplied by Ferring AB
(Limhamn, Sweden) and ritodrine (Yutopar®) was
supplied by Solvay (Taipei, Taiwan). Women who
were randomized to receive atosiban were given
a single intravenous (i.v.) bolus dose (6.75 mg 
in 0.9 mL normal saline) followed by a loading
i.v. infusion at 18 mg/hour (300 μg/minute) for
3 hours, and a subsequent i.v. infusion at 6 mg/
hour (100 μg/minute) for 15 hours. Ritodrine
was given as an i.v. infusion at an initial rate of
20 mL/hour (66.6 μg/minute) and increased by
10 mL/hour (33.3 μg/minute) every 10–30 min-
utes, until the desirable uterine response (uterine
quiescence or < 4 contractions per hour) was ob-
tained. Both atosiban and ritodrine were admin-
istered to the patients for a maximum of 18 hours
during the first treatment. Retreatment with the
study drug was allowed if there was recurrence of
preterm labor and if all eligibility criteria were
still fulfilled by the patient.
The aim was to compare efficacy, safety 
and tolerability of atosiban and ritodrine at 
conventional doses in Taiwanese women. The
primary endpoint was to compare the propor-
tion of patients who did not deliver and did not
receive alternative tocolytic therapy after 7 days
of treatment, which was defined as tocolytic 
efficacy, a composite of efficacy and tolerability.
Secondary endpoints included measurement of
other efficacy parameters such as the proportion
of patients who did not deliver after 2 days 
of treatment and did not require alternative 
tocolytic therapy. During the study, maternal,
fetal and neonatal safety profiles were moni-
tored. Other parameters such as the frequency of
uterine contractions, gestational age at delivery,
infant birth weight, number of maternal and
fetal deaths, and early drug discontinuation
with/without alternative tocolytic therapy were
also recorded.
Women could discontinue the therapy treat-
ment under the following circumstances: (1) oc-
currence of serious adverse events; (2) treatment
failure; (3) rupture of membranes during the
study; (4) significant protocol violation; (5) pa-
tient’s request; and (6) development of an inter-
current illness that would put the patient at
increased risk or invalidate the results of the study.
Any occurrences of the above circumstances were
documented.
Progression of labor, defined as initial treat-
ment failure, was assumed when any two of the
following three criteria were met: a contraction
rate ≥ 4/hour; an increase in cervical dilation of
≥ 1 cm from the initial measurement; and an in-
crease in cervical effacement of ≥ 25% from the
initial measurement. Efficacy evaluation, includ-
ing uterine contraction rate, cervical dilation and
effacement, was performed at 1, 2, 6 and 12
hours and at the end of the drug treatment at 18
hours, and thereafter at 1 and 2 days until 7 days
(primary endpoint), with or without the need for
alternative tocolytic therapy. Retreatment with the
same i.v. drug was allowed if the preterm labor
recurred within 18 hours of initial therapy, and
the inclusion criteria were still fulfilled.
Safety parameters such as maternal and fetal
heart rate, and maternal blood pressure were
recorded within the first 2 days after therapy ini-
tiation. The severity and type of adverse events
were assessed throughout the entire study pe-
riod. The patients were asked to classify the 
reported adverse events according to a severity
scale of mild, moderate or severe. The causal re-
lationship between the treatment drug and ad-
verse events was also documented and rated as
probable, possible or unlikely. Special attention
was paid to the occurrence of maternal tachycar-
dia (heart rate > 120 bpm). Also, signs of palpita-
tion, dyspnea, hyperglycemia and vomiting were
also recorded.
Routine laboratory parameters were recorded
for all treated women at baseline and after the
completion of the study.
Atosiban treatment of preterm labor
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Statistical analysis
All statistical analyses were performed using SAS
version 8.0 software (SAS Institute Inc., Cary, NC,
USA). The intention-to-treat (ITT) population was
the full analysis set in which all patients were
randomized to receive at least one of the study
drugs. The per-protocol (PP) population included
patients from the ITT population who did not
commit any protocol violations.
For evaluation of the primary endpoint, the
two-sample χ2 test with Yates’ or Fisher’s exact
test was used to evaluate the tocolytic efficacy of
the ITT population. All analyses were based on
two-tail statistics, and a statistically significant
value of p < 0.05 was sufficient for the rejection
of the null hypothesis. The 95% confidence inter-
vals (CI) for these primary endpoints were also
established. Secondary endpoint analysis was
conducted for the ITT population. Comparative
analysis between the two treatment groups was
performed by Student’s t test or two-sample 
χ2 test (or Fisher’s exact test) for continuous and
categorical data, respectively. The analyses were
based on two-tail statistics, and differences be-
tween the two groups were considered significant
at p < 0.05. Safety outcomes were analyzed by 
descriptive statistics and qualitative analysis for
all emergent adverse events, measured after initial
treatment to 4 weeks after treatment. In accor-
dance with the protocol, primary analysis was
performed using the ITT population, all secondary
endpoints were summarized as descriptive statis-
tics for the ITT population, and safety analyses
were also performed on the ITT population.
Sample size was determined using the statis-
tical program NQuery Advisor 3.0 (Statistical
Solutions, Boston, MA, USA). A sample size of
257 was required for the treatment arm in each
group to show a 12.3% increase from 47.7% 
(ritodrine response) to 59.7% (atosiban response)
in tocolytic efficacy. This was the proportion of
women who had not delivered at 7 days after
treatment initiation and did not require alterna-
tive tocolytic therapy in a worldwide comparison
of atosiban and beta-agonists in > 700 patients.13
A level of significance of 5% (α = 0.05) and a
power of 80% (β = 0.02) was used. The present
study recruited a minimum of 40 patients, ac-
cording to the suggestion of the Center for Drug
Evaluation in Taiwan.
Results
A total of 45 patients diagnosed with preterm
labor between 24 and 33 weeks gestation, con-
firmed by ultrasound, were enrolled and ran-
domized to receive atosiban (n = 23) or ritodrine
(n = 22). A trial flowchart is shown in the Figure.
All patients were included in the ITT analysis.
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All 45 patients 
Atosiban
23 patients
Ritodrine
22 patients
ITT = 23
patients
PP = 15
patients
PP = 20
patients
Completed =
23 patients
Completed =
19 patients
3 lost to follow-up
(B017, B018, B024)
4 not in PP
(B007, B034, B038, B043)
ITT = 22
patients
3 not in PP
(A003, A006, A028)
Figure. Disposition of subjects. 
ITT = intention-to-treat; 
PP = per protocol.
Among the ITT population, only 35 women com-
pleted treatment (20 in the atosiban group and
15 in the ritodrine group), and they were defined
as the PP group. In the atosiban group, three 
patients were excluded because of the protocol
requirement of the PP group. One patient deliv-
ered shortly after atosiban was administered (< 18
hours of atosiban treatment) and did not com-
plete the study; the second patient discontinued
the study after opting for cesarean section, and
the third discontinued as a consequence of fetal
distress (which had no apparent relation to the
treatment). Therefore, a total of 20 patients re-
mained in the PP group of the atosiban group. 
In the ritodrine group, three patients were lost to
follow-up after delivery but did complete the
study (patient recruitment was around the period
of SARS). Another four patients deviated from
the requirements of the PP group because of a
sub-standard ritodrine dosing regimen; therefore,
15 patients remained in the ritodrine PP group.
Demographic characteristics (Table 1) of the
atosiban and ritodrine groups were similar at 
admission (ITT population was used for analysis)
in terms of their maternal age, obstetric history,
height, weight and heart rate. The gestational age
at recruitment (p = 0.043) and systolic blood pres-
sure (p = 0.040) differed significantly between the
two groups. There was also a difference in heart
rate, although this was not statistically significant
(p = 0.065). The pretreatment values of systolic
blood pressure and heart rate fell within the nor-
mal ranges. There was no previous preterm deliv-
ery reported for any of the patients. Logistic
regression analysis showed that none of these
baseline demographic variables were associated
significantly with the primary endpoint of the
study (data not shown).
Tocolytic efficacy was accessed in terms of the
proportion of women who remained undelivered
and did not receive any alternative tocolytic ther-
apy after 7 days of treatment (primary endpoint)
(Table 2). Using the ITT population for analysis,
the rates of primary efficacy endpoint for atosi-
ban and ritodrine groups were 78.3% (18/23)
and 86.4% (19/22), respectively (p = 0.700). There
was no significant difference observed between
the two tocolytic treatments. Similarly, the pro-
portion of patients who did not deliver within 
2 days after treatment initiation and did not re-
quire alternative tocolytics was not shown to be
significantly different for atosiban 82.6% (19/23)
and ritodrine 86.4% (19/22) (p = 1.000; Table 1).
When data were analyzed in the PP group, the
number of women who remained undelivered
and did not require alternative tocolytics at 2 and
7 days were similar for atosiban 90% (18/20)
and ritodrine 100% (15/15) (p = 0.496). There
was no difference observed in the primary effi-
cacy endpoint for the atosiban and ritodrine
Atosiban treatment of preterm labor
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Table 1. Baseline demographics of the study population*
Atosiban (n = 23) Ritodrine (n = 22) p
Maternal age (yr) 31.4 ± 3.8 30.1 ± 2.4 0.146
Parity
0 14 (60.9) 15 (68.0) 0.624
≥ 1 9 (39.1) 7 (31.8)
Maternal height (cm) 159 ± 5.0 158.8 ± 5.5 0.894
Maternal weight (kg) 63.5 ± 11.2 62.6 ± 7.8 0.770
Gestational age at admission (wk) 30.3 ± 2.8 28.4 ± 2.8 0.043†
Maternal heart rate (bpm) 81.9 ± 11.7 88.9 ± 13.3 0.065
Systolic blood pressure (mmHg) 110.0 ± 12.8 117.5 ± 11.1 0.040†
Diastolic blood pressure (mmHg) 67.0 ± 8.0 68.8 ± 8.4 0.460
*Data presented as mean ± standard deviation or n (%); †p < 0.05.
groups, by both ITT and PP analysis. The propor-
tion of patients who did not deliver after initial
treatment success was 95% (19/20) and 72.2%
(16/22) for atosiban and ritodrine, respectively
(p = 0.096; Table 2). Thus, there was no signifi-
cant difference between the two groups in terms
of treatment success. Most women were treated
only once in both groups, with the number of
treatments in the atosiban group 60.9% (14/23)
and the ritodrine group 72.7% (16/22). Additional
treatment cycles were necessary for 39.1% of the
atosiban group compared with 27.3% of the 
ritodrine group.
Hyaline membrane disease is a respiratory dis-
ease of the newborn associated with prematurity.
There was no occurrence of this condition in the
atosiban group and only one recorded case (1/22)
in the ritodrine group (p = 0.489; Table 3). Other
secondary endpoints such as the frequency of
uterine contractions were monitored at 0–2 days
after therapy initiation. Overall, there were more
changes in the uterine contraction rate observed
at 0–18 hours and 0–2 days in the atosiban
group compared with the ritodrine group, even
though the differences were not statistically sig-
nificant. There was no significant difference in
maternal and perinatal outcomes, including infant
birth weight, number of episodes of recurrent pre-
term labor, gestational age at delivery, number of
days newborn infants spent in neonatal intensive
care, number of days newborn infants spent on a
ventilator, total number of days newborn infants
C.H. Lin, et al
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Table 2. Tocolytic efficacy of atosiban and ritodrine for patients without alternative tocolytic therapy who
had not delivered at 2 and 7 days, and patients with initial treatment success*
Atosiban (n = 23) Ritodrine (n = 22) 95% CI p
Tocolytic efficacy
No delivery at 2 d 19 (82.6) 19 (86.4) 0.7–0.9 1.000
No delivery at 7 d 18 (78.3) 19 (86.4) 0.7–0.9 0.700
Initial treatment success 19 (95) 16 (72.7) 0.7–0.9 0.096
*Data presented as n (%). CI = confidence interval.
Table 3. Other maternal and perinatal outcomes according to therapy
Atosiban Ritodrine
n
n (%) or 
n
n (%) or 
mean ± SD mean ± SD
p*
Hyaline membrane disease 23 0 (0) 22 1 (4.6) 0.489
Change in contraction rate/hr
0–18 hr 20 6.6 ± 4.7 22 4.9 ± 7.3 0.374
0–24 hr 19 4.7 ± 6.8 21 4.7 ± 5.1 0.977
0–48 hr 19 6.9 ± 5.4 21 5.3 ± 3.6 0.265
Gestational age upon delivery (wk) 23 37.1 ± 2.5 19 37.4 ± 2.4 0.715
Infant birth weight (kg) 23 2.9 ± 0.5 19 2.8 ± 0.4 0.516
Episodes of recurrent preterm labor 23 0.5 ± 0.7 22 0.3 ± 0.5 0.235
Days in NICU 17 3.5 ± 8.2 15 2.3 ± 6.2 0.649
Days spent on ventilator 17 0.4 ± 1.0 15 1.7 ± 4.9 0.321
Days spent in nursery 22 7.6 ± 7.8 19 7.5 ± 9.1 0.979
*Evaluates the difference between the mean value of atosiban and ritodrine. SD = standard deviation; NICU = neonatal intensive 
care unit.
spent in nursery, and proportion of patients with
illnesses/handicaps (Table 3).
In view of the low number of subjects and
outcome of adverse events, safety was evaluated
descriptively by the occurrence of adverse events,
except for the rate of tachycardia, which was com-
pared statistically using Fisher’s exact test. Overall,
the occurrence of adverse events was not signifi-
cantly different between the atosiban and ritodrine
groups; three women from the atosiban group
compared with four from the ritodrine group 
experienced adverse events (p = 0.700; Table 4).
When the adverse events were analyzed in terms
of their relationship with drug treatment (un-
known, none, possible, probable or highly prob-
able), there was no adverse event that had a
highly probable relationship with atosiban treat-
ment. However, there were three of five adverse
events in the ritodrine group that had a highly
probable relationship with drug treatment, and
two had a probable relationship; all were patients
with reported maternal tachycardia. When the
adverse events were analyzed in terms of severity
(mild, moderate or severe), no severe adverse
event was reported throughout the study. All the
adverse events were mild to moderate in severity
and were similar between the two groups (Table 4).
There was no recorded maternal or fetal death in
either treatment group.
Adverse events in the two treatment groups
were analyzed further by measuring the occur-
rence of tachycardia (heart rate > 120 bpm) or
heart rate > 100 bpm. The occurrence of tachycar-
dia was compared statistically using Fisher’s exact
test. Four patients (18.18%) in the ritodrine group
experienced tachycardia at first treatment and
none in the atosiban group, although the differ-
ence was not significant (Table 5). However, the
proportion of patients with heart rate > 100 bpm
at first treatment was significantly higher in the
ritodrine group (20/22, 90.9%) than in the atosi-
ban group (3/22, 13.6%).
Discussion
The current study was performed in Taiwan on 
a population of patients similar in their ethnic
background. There have been no previous ran-
domized trials specifically designed to examine
safety and efficacy of atosiban in the primary
treatment of spontaneous preterm labor in this
population. Our study provides further infor-
mation and understanding of the treatment of
preterm labor. Atosiban is the first oxytocin an-
tagonist to be licensed for the specific treatment
of preterm labor. It works by competing with
oxytocin for the oxytocin receptors in the uterus,
Atosiban treatment of preterm labor
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Table 4. Summary of maternal adverse events
(AEs) in relation to treatment drugs*
Atosiban Ritodrine
Total no. of women with AEs 3 4
Total no. of AEs 4 5
Relation of AE to treatment
Unknown 1 (25) 0 (0)
None 1 (25) 0 (0)
Possible 1 (25) 0 (0)
Probable 1 (25) 2 (40)
Highly probable 0 (0) 3 (60)
Severity of AE
Mild 1 (25) 1 (20)
Moderate 3 (75) 4 (80)
Severe 0 (0) 0 (0)
*Data presented as n (%).
Table 5. Proportion of patients with tachycardia or heart rate > 100 bpm at first treatment
Atosiban Ritodrine
n/total n % n/total n %
p
Heart rate > 120 bpm (tachycardia) 0/22 0 4/22 18.2 0.1080
Heart rate > 100 bpm 3/22 13.6 20/22 90.9 < 0.0001*
*p < 0.05.
which then causes inhibition of the uterine con-
tractions naturally brought on by oxytocin ex-
pression during labor. Clinical support from
international studies as well as a recent Korean
study has demonstrated that atosiban is superior
when compared with beta-agonists, with respect
to tocolytic efficacy and safety.13,14 As a result of
the specific actions of atosiban on the oxytocin
receptors in the uterus, maternal and fetal side
effects are seldom observed.1,9,13,14
The present study compared the tocolytic effi-
cacy of atosiban and beta-agonists in women
with preterm labor who did not deliver and did
not require alternative tocolytic therapy after 
7 days. This endpoint is a composite outcome of
efficacy and drug tolerability. Tocolytic efficacy
for 2 days was also measured among other sec-
ondary and safety endpoints. There was no sig-
nificant difference between atosiban and ritodrine
in tocolytic efficacy for 2 or 7 days. This result
differs from some previously reported studies of
atosiban and various beta-agonists in the treat-
ment of preterm labor, in which atosiban was
shown to be significantly superior with respect
to efficacy and safety.13,14 In a worldwide com-
parison of atosiban versus beta-agonists, the 
tocolytic efficacy was reported to be 59.7% in 
the atosiban group and 47.4% in the ritodrine
group (p = 0.0003).13 The difference in tocolytic
efficacy in the present study may be explained
partly by the small sample size compared with
that in the previous study, which included > 700
preterm patients.
The actual percentage efficacy for atosiban
and ritodrine was higher in our study compared
with that in the worldwide study. This difference
may be explained partly by the difference in 
ethnicity between the Taiwanese and worldwide
studies. Many studies have shown that obstetric
outcomes and gestational length vary by ethnic-
ity,15–18 which may explain the variations ob-
tained in studies with different ethnic backgrounds.
The incidence of preterm delivery has been shown
to be higher among Filipina women compared
with Chinese and Japanese women in a study in the
USA.15 Further studies are required to confirm
whether ethnicity really does influence tocolytic
efficacy in preterm treatment in Taiwanese women.
International clinical studies like the worldwide
atosiban and beta-agonists study can be exten-
ded to include other Asian countries, to determine
whether ethnic or cultural differences influence
preterm treatment outcomes. One of the limita-
tions of our study is the small sample size, which
may explain the difference in tocolytic efficacy
observed between the present and other reported
studies. By performing larger randomized and
international studies, we may overcome this lim-
itation and gain more information on possible
ethnic differences.
Past studies have shown that neonatal mor-
bidity is related directly to gestational age at de-
livery.18 One Cochrane review has shown that,
although atosiban is associated with fewer mater-
nal drug reactions that require treatment cessation,
it increases the number of infants born under
1.5 kg, compared with beta-agonists.19 There was
no similar finding in our study. Our data showed
that the mean gestational age for both treatment
groups was similar at 37 weeks, and that both
drugs were effective in delaying delivery, without
severe maternal side effects and similar infant
outcomes. The birth weight did not differ signifi-
cantly between the two groups (atosiban vs. rito-
drine: 2.9 ± 0.5 vs. 2.8 ± 0.4 kg). Overall, there was
no severe or serious adverse events during the 
entire study, but more tachycardia (heart rate
> 120 bpm) was observed in the ritodrine group.
Therefore, it can be concluded that the adminis-
tration of ritodrine is associated with the adverse
effect of tachycardia. Even more patients in the
ritodrine group were diagnosed with tachycardia
when the definition was changed to > 100 bpm.
Tachycardia is a common cardiovascular side ef-
fect of beta-agonists in tocolytic studies, because
of their physiological effect on β1 adrenergic re-
ceptors; therefore, it is our intention to study the
different safety profiles of the two drugs. Our 
results agree with previous studies in which sig-
nificantly more treatment discontinuation and
withdrawal was the consequence of maternal–fetal
cardiovascular adverse effects from beta-agonist
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treatment.1,5,13,14 Beta-agonist treatment has also
in the past been associated with other adverse
events such as pulmonary edema and cardiac
events.20,21 Although patients in the ritodrine
group were at an earlier gestational age at admis-
sion and had higher systolic blood pressure com-
pared with the atosiban group, further logistic
regression analysis concluded that none of the
demographic variables were associated with to-
colytic efficacy or tachycardia and other maternal
cardiovascular adverse effects (data not shown).
The higher systolic blood pressure still fell within
the normal acceptable range, thus, no bias was
introduced that might have affected the interpre-
tation of efficacy or safety results.
Overall, the present study shows that atosiban
is an effective tocolytic agent. It is better tolerated
when compared with beta-agonist treatment be-
cause of its high uterine specificity. Our results
indicate that atosiban is a promising and safe
treatment of preterm labor.
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